Becton Dickinson BDX

equity

Price History

1973-02 · DCA start$1.8

Time underwater

How far below its previous all-time high the price sat, each month. 0% means a new high.

1973-022026-08 · -16.4%

Worst drawdown: −49%, peaking Oct 1973 and bottoming Sep 1974 — 85 months below the prior high before recovering.

DCA Backtest

Start month

Monthly amount (USD)

Invested: $64,300
Value today: $2,075,661
Return: +3128.1%
Months invested: 643

Scenarios

Inflation — the same contributions merely keeping pace with CPI would be $161,137 today, so the real (inflation-adjusted) return is +1188.1%.

Lump sum instead — $64,300 all at once in Feb 1973: $6,544,716 (+10078.4%) — lump sum came out ahead.

Worst timing — same monthly amount started at the all-time high (Aug 2023): $3,998 on $3,700 invested (+8.0%).

⚠ Price returns only — dividends are not included. This understates the true return of dividend-paying shares, and any comparison against crypto (which pays no dividends) is biased against equities by roughly the dividend yield, compounded.

If this saved you a spreadsheet — buy me a coffee.

Every start month at once

Each cell is the return-to-date of £/$/€100-a-month DCA started that month. Click a cell to load it in the backtest above. The ringed cell is the all-time-high start — the worst timing scenario.

	J	F	M	A	M	J	J	A	S	O	N	D
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Legend:−50%−20%0%+50%+200%+1000%worst timing (ATH)Selected 1973-02: +3128.1%

About Becton Dickinson

Becton, Dickinson and Company is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain areas. (Wikipedia)

It's a listed company categorised under health care and health care equipment, with a market cap of about $50.0B.

It rates Medium-Low Risk at 2.1/5, meaning the rated factors are mostly sound, with one or two areas worth watching.

What pushes the score up: sector / regulatory (3.0/5) and leverage / financial (2.5/5).

Scoring well: liquidity at 1.0/5.

Not yet researched: concentration, governance. These are excluded from the score rather than guessed, so the real risk may be higher than what’s shown.

Ratings summarise sourced facts against fixed rules — not investment advice, and no substitute for your own diligence.

Risk Profile

Medium-Low Risk(2.1/5)80% rated

How these ratings work

Market / Volatility2.0/5 · weight 20%

Annualised volatility (3yr)2/522.5
Max drawdown from ATH2/549.1
Beta vs S&P 5002/50.55

Liquidity1.0/5 · weight 15%

Avg daily $ volume1/5406.2m
Float % of shares outstandingnot yet researched

Leverage / Financial2.5/5 · weight 20%

Debt / equity2/50.69
Interest coverage (EBIT / interest)3/54.2

Earnings Quality2.0/5 · weight 15%

3yr EPS volatility2/513.7

Concentrationunrated · weight 10%

Largest customer, % of revenuenot yet researched
Geographic revenue concentrationnot yet researched

Governanceunrated · weight 10%

Board independence %not yet researched
Share structurenot yet researched
Litigation / audit historynot yet researched

Sector / Regulatory3.0/5 · weight 10%

Sector regulatory exposure3/5elevated

Linked Assets

Same sector, or return-correlated — worth knowing what else might move if this one does.